A 59-year-old woman presented to the emergency department with progressive lower extremity edema. She reported persistent swelling in her lower extremities over the preceding month. She described generalized fatigue and new-onset dyspnea occurring 2 to 3 days before presentation. She reported no recent fevers, chills, cough, chest pain, orthopnea, or paroxysmal nocturnal dyspnea. Her medical history was notable only for hereditary hemorrhagic telangiectasia (HHT) manifested by frequent nosebleeds since childhood. She had undergone genetic testing at an outside institution 20 years earlier, which revealed a heterozygous mutation in the ACVRL1 gene. She had no history of hypertension, diabetes, hyperlipidemia, or tobacco use. Her only medication was a daily multivitamin.
The patient's oxygen saturation was 88% on room air, and supplemental oxygen was administered via nasal cannula. Her blood pressure was 132/65 mm Hg with a heart rate of 110 beats/min. Her body mass index (reference ranges provided parenthetically) was 38.9 kg/m 2 (18.5-24.9 kg/m 2 ). Physical examination was notable for: lower lip telangiectasias; a grade 2/6 holosystolic murmur best heard in the left lower sternal border, which increased in intensity with inspiration; jugular venous pressure of 12 cm (8 cm) with the patient semirecumbent (45 degrees); positive hepatojugular reflux; pulsatile liver; and 2þ pitting edema to the level of the knees, bilaterally. An atypical pneumonia can present with hypoxia and dyspnea, but it is usually associated with fevers and cough. The patient's jugular venous distention, liver pulsatility, tricuspid regurgitation murmur, and pitting edema are consistent with RV heart failure. Liver cirrhosis can result in high-output heart failure; however, she does not have other sequelae of decompensated cirrhosis (ascites, hepatic encephalopathy, or jaundice). In addition, liver cirrhosis does not lead to a pulsatile liver. The lack of chest pain and traditional risk factors associated with atherosclerotic cardiovascular disease makes acute coronary syndrome less likely. Although venous insufficiency is a common cause of lower extremity edema, this would not explain the patient's hypoxia or other cardiopulmonary findings noted on physical examination.
Laboratory testing demonstrated the following: hemoglobin, 10.4 g/dL (12-15.5 g/dL); mean corpuscular volume, 73.8 fL (81.6-98.3 fL); and B-type natriuretic peptide, 1354 pg/mL (91 pg/mL). An electrocardiogram revealed atrial flutter with 2:1 conduction; no relevant ST-segment or T-wave changes were noted. Computed tomography (CT) with contrast media showed the following: bilateral pulmonary arteriovenous malformations (AVM) (largest 4.8 x 3.7 cm); multiple hepatic AVMs (largest 2.8 x 1.7 cm); marked dilatation of the central pulmonary arteries without any arterial filling defects; rightsided cardiac chamber enlargement; and a right pleural effusion. No emphysematous changes, ground-glass opacities, or areas of consolidation were noted. Ventilation-perfusion lung scan revealed bilateral segmental perfusion defects without matched ventilation defects that did not correspond with the pulmonary AVMs noted on CT, considered to be highly probable for pulmonary embolism. Transthoracic echocardiography demonstrated severe RV enlargement, severely decreased RV systolic high-flow state, which in turn results in increased pulmonary pressures e. There is low suspicion for heart failure with preserved ejection fraction as a contributing factor to this patient's pulmonary hypertension
The World Health Organization classification of pulmonary hypertension comprises 5 groups: PAH (group 1); pulmonary hypertension due to left-sided heart disease (group 2); pulmonary hypertension due to chronic lung disease and/or hypoxia (group 3); chronic thromboembolic pulmonary hypertension (CTEPH; group 4); and pulmonary hypertension due to unclear multifactorial mechanisms (group 5). 1 Although the sensitivity of CT angiography in detecting acute pulmonary embolism is somewhat variable (in part due to pretest probability), it is generally accepted to be greater than 90%. However, chronic thromboembolic disease, which can increase pulmonary pressures and cause RV dysfunction, may be missed by a CT scan. 2 The ventilation-perfusion mismatch identified on ventilation-perfusion scan also raises concern for pulmonary embolism. Pulmonary arterial hypertension is a proliferative vasculopathy characterized by restricted flow through the pulmonary arterial vasculature, which in turn causes elevated RV pressures and eventual right-sided heart failure. Pulmonary arterial hypertension can be seen in familial disorders such as HHT and therefore is a plausible explanation for this patient's pulmonary hypertension and RV dysfunction. Although COPD may be associated with mild pulmonary hypertension, it is very rarely the only etiology of right-sided heart failure. 3 In addition, the patient had no history of tobacco use or evidence of emphysematous disease to suggest that she had underlying COPD. The large hepatic AVMs seen on CT can create a high-flow state from left-to-right shunting and trigger high-output heart failure with subsequent RV dysfunction. The patient had risk factors associated with heart failure with preserved ejection fraction (atrial arrhythmias and obesity), which can lead to elevated pulmonary capillary wedge pressures (PCWPs) and group 2 pulmonary hypertension.
Despite attempts at diuresis, the patient remained substantially dyspneic with minimal activity. To determine next steps in management, additional testing to elucidate the underlying etiology of her cor pulmonale was pursued.
3. Which one of the following is the most appropriate next step in evaluating this patient's condition? a. Right-sided heart catheterization (RHC) b. Dobutamine stress echocardiography c. Regadenoson radionuclide myocardial perfusion imaging d. Transesophageal echocardiography e. Cardiac magnetic resonance imaging Right-sided heart catheterization is the criterion standard for the evaluation and diagnosis of pulmonary hypertension and is therefore the most appropriate test in this scenario. Pharmacological stress testing modalities, such as dobutamine stress echocardiography and regadenoson radionuclide myocardial perfusion imaging, are helpful in the identification of underlying coronary artery disease but do not contribute additional information regarding the cause of the patient's pulmonary hypertension. Transesophageal echocardiography provides complementary views of cardiac structures and may identify intracardiac shunts not visualized on transthoracic echocardiography; however, it does not provide the hemodynamic data required in the work-up of pulmonary hypertension. Cardiac magnetic resonance imaging allows for detailed visualization of cardiovascular anatomy and function, and it can be clinically useful in the assessment of multiple disorders, including cardiomyopathy and pericarditis. 4 However, it is not the first-line test for identifying the etiology of pulmonary hypertension.
The In a normal individual, systemic flow should be equivalent to pulmonary flow. In this patient, the two differ (Qs/Qp, 1.3), consistent with a small, extracardiac, left-toright shunt due to the presence of hepatic AVMs. The known pulmonary AVMs point toward the possibility of intrapulmonary shunting. However, the fact that her arterial oxygen saturation normalized with oxygen supplementation makes this less likely. Measuring PCWP provides an estimate of left atrial pressure through "wedging" of a balloon-tipped, end-hole catheter in the distal pulmonary vasculature. In this patient, a high PA pressure in the presence of normal PCWP indicates that her pulmonary hypertension is not due to leftsided heart failure. In the absence of left-sided heart disease, chronic lung disease, and CTEPH, the elevated pulmonary vascular resistance is consistent with intrinsic pulmonary vascular disease due to group 1 PAH associated with HHT. Vasodilator administration during RHC is used to identify patients who may respond to high-dose calcium channel blocker therapy. 5 A positive response is defined as a decrease in mean PA pressure of 10 mm Hg or more to an absolute value of 40 mm Hg or less without a decrease in cardiac output. The patient did not meet criteria for a positive response during vasodilatory testing, and therefore calcium channel blockers are unlikely to be effective.
Hereditary hemorrhagic telangiectasiae associated PAH was diagnosed on the basis of the hemodynamic data, and the decision to initiate PAH-specific vasodilator therapy was made. Embolization of the hepatic AVMs was considered but not pursued given the lack of efficacy in improving hemodynamics and the high risk of complications (ischemic hepatitis, hepatic encephalopathy, and pain) associated with the procedure. Several targeted therapies have been developed to decrease resistance through the pulmonary circuit and thereby improve overall blood flow. 3, 5, 7 Treprostinil is a prostanoid analogue that has vasodilatory and antiproliferative effects on the pulmonary arteries. Administered via inhalation or through subcutaneous/intravenous infusions, it is associated with an improvement in exercise capacity but not mortality. 7 Sildenafil causes vasodilation through the nitric oxide/cyclic guanosine 3 0 ,5 0 -mono phosphate pathway via the inhibition of phosphodiesterase type 5. On the basis of data from 4 randomized controlled trials, it is associated with improvements in exercise capacity, symptoms, and hemodynamics; however, no trial data have confirmed a mortality benefit. 5 Iloprost is an inhaled prostanoid analogue that has been found to improve exercise capacity and symptoms but not mortality. 5 Macitentan acts as an antagonist of the endothelin 1 pathway, which promotes vasoconstriction and mitogenesis in the pulmonary arterial vasculature. In the SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome) trial, macitentan was associated with lower rates of morbidity and mortality than placebo. 8 Riociguat is a soluble guanylate cyclase stimulator that improves exercise capacity and symptoms in patients who have PAH and CTEPH; however, no survival benefit has been found. 5 No randomized controlled trials have been conducted to evaluate outcomes of pharmacological therapy in HHT-associated PAH, owing to its relative rarity. 9 Given the patient's clinical symptoms, severely elevated PA pressure, and RV dysfunction, a combination therapy of intravenous treprostinil with oral sildenafil and macitentan was initiated under the guidance of the Pulmonary Hypertension consultative service. Despite administration of these medications, oliguric acute kidney injury secondary to cardiorenal syndrome developed, requiring renal replacement therapy. Her hospital course was additionally complicated by bilateral soleal vein thromboses and an RV thrombus; therapeutic anticoagulation with warfarin was therefore initiated. She improved clinically after a month of inpatient medical treatment and was subsequently discharged home with outpatient dialysis.
DISCUSSION

Hereditary hemorrhagic telangiectasia, or
Osler-Weber-Rendu syndrome, is a familial vascular disorder that is associated with the formation of abnormal blood vessels within mucocutaneous tissues. 10 It exhibits an autosomal dominant pattern with variable penetrance. Three putative disease-causing genes are available for laboratory testing: ENG (HHT type 1); ACVRL1 (HHT type 2); and MADH4 (combined syndrome of HHT and juvenile polyposis syndrome). 9 The Curaçao criteria for diagnosing HHT include (1) spontaneous, recurrent nosebleeds, (2) mucocutaneous telangiectasias at characteristic sites, including fingertips, lips, and oral mucosa, (3) visceral involvement, including gastrointestinal telangiectasias and cerebral, pulmonary, and/or hepatic AVMs, and (4) family history of an affected first-degree relative. 10 Definite and suspected HHT are defined as having fulfilled 3 or more and 2 of the 4 criteria, respectively, whereas the presence of 0 to 1 criterion makes the diagnosis unlikely.
Pulmonary vascular disease is common in patients who have HHT. Pulmonary AVMs are found in approximately 50% of patients who have HHT and may result in hypoxia from right-to-left shunting and increase the risk of paradoxical embolism. 9 Pulmonary hypertension is another manifestation of HHT that occurs via 2 main mechanisms: (1) increased flow from left-to-right shunting (usually from hepatic AVMs) leading to high-output heart failure and (2) PAH due to true fibroproliferative arteriopathy. 9 Various mutations in HHT have been associated with a higher risk of PAH; specifically, ACVRL1 mutations have been implicated in patients with HHT who have concomitant PAH. 9 Pulmonary hypertension due to high-output heart failure may be managed by salt restriction and diuretics. 11 Antiangiogenic agents such as bevacizumab may also be useful in reducing high cardiac output among patients who have hepatic AVMs. 12 Transarterial embolization or surgical ligation of hepatic AVMs can be considered as well, although these procedures are associated with substantial morbidity and mortality risk. 6 Finally, liver transplant is a potentially curative option for patients who have refractory high-output heart failure from hepatic AVMs. 6, 11 Pulmonary arterial hypertension is rare among patients who have HHT (estimated prevalence of <1%), 11 so treatment options are extrapolated from standard guidelines used in PAH. 9 In addition to the vasodilator therapies described earlier, other aspects of treating HHTassociated PAH include supervised exercise
